Breaking News

Orgenesis, ATMI in Process Development Pact

May 9, 2013

Will use ATMI’s SUB technology

Orgenesis Ltd. has entered into a process development agreement with ATMI, Inc., a global technology company and provider of single-use bioprocess solutions. ATMI will supply Orgenesis with a complete disposable manufacturing process for the expansion of a patient's liver cells outside of the body for the development of a therapeutic technology that creates insulin-producing cells as a treatment for diabetes. The two companies have also entered into a subscription agreement under which ATMI purchased $1.3 million of Orgenesis shares.
"We believe the groundbreaking Integrity Xpansion technology from ATMI will allow us to produce a sufficient amount of AIP (Autologous Insulin Producing) cells for transplantation back to the patient's liver in a highly efficient and cost-effective manner," said Sav DiPasquale, chief executive officer of Orgenesis. "We look forward to building a successful relationship with ATMI, another very strong collaboration partner for Orgenesis as we continue to work towards initiating clinical trials of our technology."
Senior vice president and general manager of ATMI LifeSciences, Mario Philips, said, "The Integrity Xpansion Multiplate Single-Use Bioreactor technology was specially developed by ATMI for addressing the scaling-up challenges of cell therapy manufacturing processes. This fully industrial technology platform is very suitable for adherent fragile cell culture applications, such as the adult liver cells. We are very excited to provide this technology to Orgenesis as they work to develop a very promising new therapy for diabetes that overcomes the problem of donor shortage and reduces the risk of transplant rejection."

Related Contract Manufacturing:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials